- Home
- TWIN vs VTYX Comparison
TWIN vs VTYX Comparison
Compare TWIN & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- VTYX
- Stock Information
- Founded
- TWIN 1918
- VTYX 2018
- Country
- TWIN United States
- VTYX United States
- Employees
- TWIN N/A
- VTYX N/A
- Industry
- TWIN Industrial Machinery/Components
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- TWIN Industrials
- VTYX Health Care
- Exchange
- TWIN Nasdaq
- VTYX Nasdaq
- Market Cap
- TWIN 182.9M
- VTYX 184.6M
- IPO Year
- TWIN N/A
- VTYX 2021
- Fundamental
- Price
- TWIN $12.40
- VTYX $2.45
- Analyst Decision
- TWIN
- VTYX Buy
- Analyst Count
- TWIN 0
- VTYX 5
- Target Price
- TWIN N/A
- VTYX $8.40
- AVG Volume (30 Days)
- TWIN 27.6K
- VTYX 2.0M
- Earning Date
- TWIN 02-05-2025
- VTYX 11-07-2024
- Dividend Yield
- TWIN 1.32%
- VTYX N/A
- EPS Growth
- TWIN N/A
- VTYX N/A
- EPS
- TWIN 0.68
- VTYX N/A
- Revenue
- TWIN $304,470,000.00
- VTYX N/A
- Revenue This Year
- TWIN N/A
- VTYX N/A
- Revenue Next Year
- TWIN N/A
- VTYX N/A
- P/E Ratio
- TWIN $17.94
- VTYX N/A
- Revenue Growth
- TWIN 6.98
- VTYX N/A
- 52 Week Low
- TWIN $10.83
- VTYX $1.67
- 52 Week High
- TWIN $18.00
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- TWIN 53.73
- VTYX 49.27
- Support Level
- TWIN $11.82
- VTYX $2.41
- Resistance Level
- TWIN $12.50
- VTYX $3.39
- Average True Range (ATR)
- TWIN 0.48
- VTYX 0.26
- MACD
- TWIN -0.02
- VTYX -0.04
- Stochastic Oscillator
- TWIN 41.48
- VTYX 11.64
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.